Since anti-MDA5 (+) CADM was recognized before the spread of COVID-19, we assume that some viruses (recognized by MDA5), which are common in Asia, may be risk factors for the development of anti-MDA5 (+) CADM, including myocardial damage. This evidence concerns the gene IFIH1 and COVID-19.